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Abstract. The efficacy of resveratrol as a preventive agent 
against the growth of t(4;11) acute lymphoblastic leukemia 
(ALL) was evaluated in NOD.CB17-Prkdcscid/J mice engrafted 
with the human t(4;11) ALL SEM cell line. SEM cells were 
injected into the tail vein and engraftment was monitored by 
flow cytometry. Once engraftment was observed, mice were 
injected intraperitoneally with resveratrol (10 mg/kg body 
weight) dissolved in dimethylsulfoxide (DMSO) or DMSO alone 
(control) every other day, or vincristine (0.5 mg/kg body weight) 
3 times per week for 4 weeks (n=16 per group). Comparisons of 
the percent of human leukemia cells in blood and survival curves 
showed resveratrol did not inhibit progression of the disease. 
Liquid chromatography-tandem mass spectrometry analyses 
of mouse sera showed resveratrol was rapidly metabolized to 
glucuronidated and sulfated forms 1 h post-injection, with low 
to no resveratrol or metabolites observed in sera by 24-48 h. 
These data indicate that in contrast to findings in in vitro models, 
parenterally administered resveratrol does not have potential as 
a preventive agent against high risk t(4;11) ALL.
Introduction
Resveratrol (3,5,4'-trihydroxy-trans-stilbene) is a member of 
the phytoalexin class of antibiotics and its production can be 
induced in a variety of plants in response to fungal infections, 
environmental stress, or injury (1). Resveratrol is a well-known 
component of the skin of grapes, is present in high concentra-
tions in red wine, and is also found in other plant foods including 
blueberries, mulberries, rhubarb, and cranberries. Jang et al (2) 
were the first to describe the ability of resveratrol to inhibit events 
associated with the initiation, promotion, and progression of 
cancer. Subsequent to the report by Jang et al, numerous in vitro 
and in vivo investigations have provided support for the concept 
that resveratrol may be efficacious in the prevention of certain 
cancers. Resveratrol has been shown to act as a chemopreventive 
agent against chemically-induced mammary and esophageal 
carcinogenesis in rats (3,4), lung cancer and transplanted liver 
tumors in mice (5,6), and has been reported to suppress the 
growth of aberrant crypt foci in the colon (7). Resveratrol given 
to A/J mice at a daily intraperitoneal (i.p.) dose of 40 mg/kg 
body weight for 28 days significantly inhibited the growth of 
subcutaneously xenografted neuroblastoma cells in mice (8). A 
6-fold decrease in tumor volume and a significantly improved 
survival rate (70%) were observed in the mice receiving resve-
ratrol compared to control mice. Resveratrol has been shown to 
inhibit proliferation and induce apoptotic cell death in a number 
of different types of cancer cells in vitro. Numerous reports 
have been published on the potential mechanisms that might 
contribute to the anti-cancer activity of this compound (1,9-11). 
Mechanistic studies have revealed that resveratrol can act as an 
antioxidant, inhibit transcription factor activation, and inhibit 
kinase pathways involved in cell signaling, including those 
involved in progression of the cell cycle.
Acute lymphoblastic leukemia (ALL) with chromosomal 
translocation t(4;11) is a highly aggressive leukemia found in 
60-85% of infants, 2% of children, and 3-6% of adults with ALL 
(12,13). The presence of this translocation is strongly associated 
with poor responses to conventional chemotherapeutic agents, 
relapse, and a poor prognosis for survival. The mechanisms 
underlying the malignancy of t(4;11) ALL are poorly understood. 
Defective or dysregulated apoptotic pathways during hematopoi-
esis may play a role in the generation of these leukemias. Several 
cell lines have been established from patients with ALL carrying 
the t(4;11) (q21;q23) chromosomal translocation, and these lines 
provide useful tools to evaluate the efficacy of alternative preven-
tive and therapeutic strategies (14-16).
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The nonobese diabetic/severe combined immunodeficient 
(NOD/SCID) mouse model has been successfully used to 
examine chemotherapeutic strategies against hematopoietic 
cancers (17-20). It was shown that engraftment of ALL in these 
mice mimics the human disease by homing to bone marrow, 
spleen, and liver, with significant presentation in peripheral 
blood (18,21). We have shown that resveratrol can effectively 
induce apoptotic cell death in vitro in cell lines that were estab-
lished from patients with ALL that carry the t(4;11) (q21;q23) 
chromosomal translocation, as well as other ALL lines without 
the translocation (22). We hypothesized that resveratrol would 
be efficacious in the treatment of high-risk t(4;11) ALL in vivo. 
In the present study, we evaluated the efficacy of parenterally 
administered resveratrol in the NOD/SCID mouse model after 
engrafting the SEM cell line that carries the t(4;11) translocation. 
Resveratrol was compared to a standard chemotherapeutic agent, 
vincristine, that is used in clinical settings to treat t(4;11) ALL 
(23). Serum levels of resveratrol and metabolites were measured 
by liquid chromatography/mass spectrometry (LC/MS) to deter-
mine whether parenteral administration would provide the levels 
of resveratrol needed to prevent the growth of this leukemia.
Materials and methods
Cells and reagents. SEM is an established cell line from a patient 
diagnosed with high-risk pre-B ALL containing the chromo-
somal translocation t(4;11)(q21;q23) (14). The cells were grown 
at 37˚C, 5% CO2 in RPMI-1640 (Invitrogen, Carlsbad, CA) 
supplemented with 10% fetal bovine serum (Sigma, St. Louis, 
MO), 50 IU/ml penicillin, 50 µg/ml streptomycin, 0.25 µg/ml 
amphotericin B, 1 mM sodium pyruvate, and 2 mM L-glutamine 
(Invitrogen). For injection into mice, SEM cells were harvested, 
washed twice in Dulbecco's phosphate-buffered saline (PBS) 
without Ca2+ or Mg+ (Sigma), and resuspended at a final concen-
tration of 50x106 cells/ml in PBS.
Vincristine sulfate and resveratrol (>99% pure) were pur-
chased from Sigma. Vincristine sulfate was dissolved in PBS. 
Resveratrol was dissolved in dimethylsulfoxide (DMSO, Sigma). 
The solutions were filter sterilized, aliquoted, and frozen at 
-20˚C until use. Phycoerythrin-cyanin 7 (PE-Cy7)-conjugated 
anti-human CD19, allophycocyanin-Cy7 (APC-Cy7) conjugated 
anti-mouse CD45 were purchased from Becton-Dickinson (San 
Jose, CA). The trans-isomers of resveratrol, tetra-deuterated 
resveratrol (d4-resveratrol), resveratrol-3-O-D-glucuronide, 
resveratrol-4'-O-D-glucuronide, and resveratrol-3-O-sulfate, and 
1-cyclohexyluriedo-3-dodecanoic acid (CUDA) were obtained 
from Cayman Chemical Co. (Ann Arbor, MI). Sulfatase from 
Aerobacter aerogenes, β-glucuronidase (Type IX-A) from 
Escherichia coli, formic acid, glycerol, potassium 4-nitrophenyl 
sulfate, and 4-nitrophenyl β-D-glucuronide were purchased from 
Sigma. Ammonium hydroxide and LC/MS grades of methanol, 
acetonitrile, and water were obtained from Fisher Scientific (Fair 
Lawn, NJ). Normal mouse serum was obtained from United 
States Biological (Swampscott, MA).
Immunodeficient NOD/SCID mice. All experimental procedures 
were approved by the University of California Davis Institutional 
Animal Care and Use Committee. Five- to six-weeks-old female 
NOD.CB17-Prkdcscid/J mice were purchased from the Jackson 
Laboratory (Bar Harbor, ME, common name NOD/SCID). 
Mice were housed and handled under pathogen-free conditions 
at the University of California, Davis vivarium in a tempera-
ture controlled environment with a 12-h light-dark cycle. Mice 
were fed a commercial rodent diet (Diet 7013, Harlan Teklad, 
Madison, WI) that was sterilized by gamma irradiation. Mice 
were given sterilized food and water ad libitum. Mice were 
weighed once per week in a biosafety cabinet to maintain 
pathogen-free conditions. At the age of 8 weeks, each mouse 
was injected with 5x106 SEM cells through the tail vein using 
a 1-cm3 syringe with a 30-G needle (Becton-Dickinson). The 
injection volume was 100 µl.
Detection of leukemia cell engraftment. Beginning 2 weeks after 
the tail vein injections of leukemia cells, ~50 µl of blood was 
collected from the tail artery of each mouse once per week to 
monitor engraftment of the human leukemia cells. Blood was 
collected directly into heparinized Microvette tubes (Sarstedt, 
Newton, NC) and transferred to 1.5 ml microfuge tubes, where 
red blood cells were lysed using PharmLyse (Becton-Dickinson) 
according to the manufacturer's recommendation. The peripheral 
blood leukocytes (PBLs) were stained with PE-Cy7 conjugated 
anti-human CD19 and APC-Cy7 conjugated anti-mouse CD45 
at room temperature for 20 min. The cells were washed in PBS 
containing 0.1% BSA and 7 mm sodium azide (Sigma) and then 
fixed in 1% paraformaldehyde (Sigma) before analysis by flow 
cytometry. The stained cells were analyzed on a FACSCanto™ 
fluorescence-activated cell sorter (FACS) using FACSDiva™ 
software (Becton-Dickinson). Each analysis of peripheral blood 
cells was performed using appropriate scatter gates to exclude 
cellular debris and aggregated cells. PBLs prepared from NOD/
SCID mice not injected with leukemia cells were used as a nega-
tive control for engraftment. These cells were frozen at -80˚C 
in 10% DMSO, 90% fetal bovine serum until use. As a positive 
control for CD19+ cells, SEM cells were added to an aliquot of 
thawed PBLs from non-engrafted mice. The negative and posi-
tive control cells were stained as described above and used to set 
the gates for human CD19+ cells. Thirty thousand events were 
collected for each sample. Positive engraftment was established 
when the proportion of human CD19+ cells reached 1% in the 
murine PBL population (17,18).
Initial treatment with resveratrol and toxicity assessment. 
Once engraftment of leukemia was observed in the peripheral 
blood, mice were randomly separated into control, resveratrol, 
and vincristine treatment groups (n=13-14 per group). The mice 
were treated daily with i.p. injections of DMSO and resveratrol 
(40 mg/kg body weight), or once per week with vincristine 
(0.5 mg/kg body weight). The 40 mg/kg dose of resveratrol was 
chosen because it was reported to be effective against neuro-
blastoma in mice (8). The approximate volume per injection was 
between 80-120 µl depending upon the weight of the mouse. 
During the treatments, the blood from each mouse was moni-
tored for growth of the leukemia cells by flow cytometry. Body 
weights were obtained weekly in order to adjust the quantity of 
chemical per animal.
The 40-mg/kg dose of resveratrol proved toxic to the 
leukemic NOD/SCID mice, requiring a toxicity analysis. Sixteen 
mice were separated into groups of 4 mice each and treated i.p. 
daily with DMSO, or doses of resveratrol at 5, 10, or 20 mg/
kg body weight for one week. After one week, the mice were 
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injected with the same doses once every other day for 3 weeks. 
The mice were monitored daily for signs of illness.
Treatment with resveratrol at a lower concentration. Forty-eight 
mice (age of 8 weeks) were injected with SEM leukemia cells as 
described above. Once engraftment of leukemia was observed 
in the peripheral blood by flow cytometry, mice were randomly 
separated into control, resveratrol, or vincristine treatment 
groups (n=16 per group). The mice were treated every other day 
with i.p. injections of DMSO and resveratrol (10 mg/kg body 
weight), or three times per week with vincristine (0.5 mg/kg body 
weight). The mice were treated for 4 weeks. Body weights and 
percent of human CD19+ cells in the mouse PBMC population 
were measured weekly. For this experiment, volumes of DMSO 
and resveratrol were reduced to 40-60 µl per mouse according 
to body weight. Injection volumes of vincristine were between 
80-130 µl per mouse.
Analysis of engraftment sites. Blood, spleens, and bone marrow 
were harvested from 4 mice from the DMSO treatment group 
following euthanasia to confirm engraftment sites of the SEM 
leukemia cells. PBLs were prepared as described above. Spleens 
were removed, placed in RPMI medium, and perfused with 
medium using a syringe and 25 G needle. The spleens were 
then shredded using the end of the needle, the cells that were 
released into the medium were collected, and the red blood cells 
were lysed with PharmLyse. Both femurs from each mouse 
were placed into RPMI medium and the ends of the femurs 
were cut. Bone marrow was removed by perfusing the inside of 
the bone with medium using a 27-G needle with syringe. PBLs, 
splenocytes, and bone marrow cells were stained with PE-Cy7 
conjugated anti-human CD19 and APC-Cy7 conjugated anti-
mouse CD45 and analyzed by flow cytometry as described 
above.
Quantification of resveratrol and resveratrol metabolites. 
Protocols optimizing resveratrol metabolite deconjugation and 
resveratrol extraction from mouse sera, and ultra performance 
liquid chromatography-tandem mass spectrometry (UPLC-MS/
MS) quantification were developed for this study. Serum from 
each mouse was removed from -70˚C, thawed on ice, and sepa-
rated into three 25-µl aliquots. Each aliquot was spiked with 
nitrophenyl glucuronide and nitrophenyl sulfate, each at a final 
concentration of 0.5 µM as digestion controls, and d4-resvera-
trol at a final concentration of 2 µM as a recovery surrogate. 
Positive controls were prepared in each analytical batch from 
three 25 µl aliquots of commercially available normal mouse 
serum prepared as above, which also received resveratrol, resve-
ratrol-3-sulfate, and the two resveratrol glucuronides at the final 
concentrations shown in Table Ι. The aliquots from each tripli-
cate set were then spiked with either 5 µl 0.1 mM ammonium 
formate pH 6.9 (mock digest), 5 µl (0.5 kU) β-glucuronidase 
reconstituted in formate buffer, or 10 µl sulfatase (0.11 U) as 
supplied. Samples were incubated at 37˚C for 1 h in an orbital 
water bath (Boekel, Feasterville, PA) at 60 Hz protected from 
light. Reactions were chilled and quenched with 100 µl cold 
acetonitrile using a 5 min 4˚C vortex. Samples were further 
chilled at -20˚C for 10 min to assist protein precipitation, and 
centrifuged at 14,000 x g for 10 min at 4˚C. Sample supernatants 
were removed to a screw capped polypropylene tube containing 
5 µl 50% methanolic glycerol, pellets were re-extracted with 
100 µl acetonitrile, and extracts were pooled. The extracts were 
dried using a Savant SV110A SpeedVac (Savant Instrument 
Inc., Holbrook, NY) and reconstituted in 100 µl 100 nM CUDA 
in methanol. After vortexing, the reconstituted extracts were 
filtered with 0.1 µm Amicon Ultrafree-MC durapore PVDF 
filter (Millipore, Billerica, MA) for 4 min at 4,000 x g and 
transferred to a glass insert in 2 ml amber vials, capped, and 
stored at 4˚C for LC-MS/MS analysis. In addition, the digestion 
and extraction controls described above, each extraction batch 
also contained mock digested, unspiked aliquots of normal 
mouse serum samples whose extracts were enriched with target 
analytes just before filtration. These samples served as a ‘matrix 
normalization solution’ allowing assessment of matrix effects 
upon the analyte detection. Methanol normalization solutions 
were prepared by spiking 100 µl of 100 nM CUDA with 1 µl 
of the spike used for matrix normalization solutions, and were 
analyzed as a further control. With each batch of samples, a 
seven point standard curve was constructed ranging from 1 to 
3,000 nM of resveratrol, resveratrol sulfate and glucuronides, 
and nitrophenyl sulfate and glucuronide in a methanolic solution 
of 100 nM CUDA and 2 µM d4-resveratrol.
Table I. Analyte specific API 4000 QTrap MS/MSa and control sample parameters.
Analyte Precursor (m/z) Product (m/z) +DCP (V) +CE (V) Spiked normal serum (µM)
Resveratrol 227.32 185.21 -80 -30 0.60
Resveratrol-d4 231.32 188.21 -80 -30 2.0
Resveratrol-3-O-D-glucuronide 403.32 227.32 -15 -37 0.20
Resveratrol-4'-O-D-glucuronide 403.32 227.32 -15 -37 0.20
Resveratrol-3-O-sulfate 307.32 227.32 -40 -30 0.20
Potassium 4-nitrophenyl sulfate 218.2 138.2 -50 -30 0.50
4-Nitrophenyl β-D-glucuronide 314.2 138.2 -50 -30 0.50
CUDA 339.36 214.2 -65 -30 -
a4000 QTrap parameters: ionspray voltage, 4.5 kV; curtain gas flow, 40 ml/min; collision gas, high; heater and source temperatures, 500˚C; 
EP/CXP - 10 V; Gas 1/Gas 2, 40 ml/min.
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Chromatographic separation was achieved using a gradient 
of acidified water and acetonitrile on a 2.1x150 mm, 1.7 µm 
Acquity UPLC BEH C18 column on an Acquity ultra perfor-
mance liquid chromatograph (UPLC, Waters Corp., Milford, 
MA). Sample were held at 10˚C and aliquots (10 µl) were 
injected on to the 50˚C column equilibrated with 90/10 v/v 
0.1% formic acid:acetonitrile. Initial conditions were held for 
1 min, ramped to 65% acetonitrile at 7 min, 95% acetonitrile at 
8 min and held for 2 min. Solvent flow was 0.25 ml/min. Mass 
spectral analysis of the UPLC effluent was performed with 
an API 4000 QTrap tandem mass spectrometer (AB SCIEX, 
Foster City, CA) using negative electrospray ionization (ESI-) 
in multiresidue mode (MRM). Optimized analyte parameters 
are summarized in Table I. Data analysis was performed using 
Analyst 1.4.2 (AB SCIEX). All analyte signals were measured 
as peak area ratios to the internal standard, CUDA, to correct for 
variability in sample volume, injection volume, and instrumental 
drift. Resveratrol serum concentrations were determined from 
1/x weighted linear regressions of methanolic standard curves 
described above. Reported serum resveratrol concentrations are 
corrected for procedural losses by dividing CUDA-linked results 
by the fractional recovery of d4-resveratrol in each sample. The 
limit of detection of resveratrol was based on visually defined 
peaks with a signal to noise ratio >2 (24).
Statistical analysis. For statistical comparisons between treat-
ment groups, the event-free survival (EFS) was calculated 
beginning with the initiation of treatment. An event was defined 
as overt clinical illness necessitating euthanasia, which included 
>20% weight loss, lethargy, severe weakness, or inability to reach 
food or water for 24 h. All statistical analyses were performed 
with GraphPad software (GraphPad Software, Inc., San Diego, 
CA) and data are displayed as arithmetic means ± standard 
deviation (SD), unless otherwise noted. One-way and two-way 
analysis of variance (ANOVA) were used to compare body 
weights, percent engraftment at the beginning of treatment, and 
percent CD19+ cells over time with Bonferroni post-tests. EFS 
was analyzed by Kaplan-Meier plots with differences calculated 
using the log-rank test. Differences were considered significant 
for α (p<0.05).
Results
Resveratrol toxicity in leukemic mice. Engraftment in the mice 
as determined by flow cytometry was 100% for both of the 
engraftment/treatment experiments. A 40-mg/kg body weight 
dose of resveratrol was used successfully to treat subcutane-
ously xenografted neuroblastoma cells in mice (8). Therefore, 
we used this dose in our initial experiments. However, with daily 
i.p. injections of 40 mg/kg resveratrol, survival of the leukemic 
mice was greatly reduced compared to both the DMSO control 
and vincristine-treated mice (Fig. 1, p<0.05, log-rank test). 
Approximately 36% of mice in the resveratrol group survived 
compared to 69% in the DMSO control group and 93% in the 
vincristine group by day 12 of treatment. The experiment was 
ended on day 13 of treatment and all mice were euthanized.
A toxicity test with lower doses of resveratrol was performed 
to determine the highest acceptable dose for treatment. Doses of 
resveratrol at 5, 10, and 20 mg/kg body weight were evaluated 
in non-leukemic NOD/SCID mice. Mice were injected i.p. daily 
for one week. We found that these mice were intolerant to the 
80-120-µl volumes of DMSO, and exhibited temporary weak-
ness in the hindlimbs after injections. Therefore, after the first 
week of daily injections, the treatment was changed to every 
other day and was continued for a further 3 weeks. A resveratrol 
dose of 10 mg/kg body weight in a 40-60-µl volume of DMSO 
administered every other day was determined to be the optimal 
volume and concentration that did not show toxicity (data not 
shown).
Intraperitoneal administration of resveratrol does not kill t(4;11) 
ALL. Resveratrol was administered i.p. at a dose of 10 mg/kg 
body weight to leukemic mice every other day. To reduce the 
hindlimb weakness that was observed with the DMSO, the injec-
tion volumes of the DMSO control vehicle and resveratrol were 
Figure 1. Resveratrol at a concentration of 40 mg/kg body weight was toxic to 
NOD/SCID mice engrafted with t(4;11) acute lymphoblastic leukemia (ALL). 
Mice were engrafted with the t(4;11) ALL line SEM, and then treated intra-
peritoneally with either DMSO (n=13) or resveratrol (40 mg/kg body weight, 
n=14) daily, or vincristine (0.5 mg/kg body weight, n=13) one time per week 
for 4 weeks. Mice were euthanized when they became clinically ill, i.e., showed 
>20% weight loss, lethargy, weakness, or inability to reach food or water. 
Differences in survival after treatment began were determined by log-rank test. 
The asterisk indicates a significant reduction in survival for resveratrol-treated 
mice compared to the DMSO and vincristine treated mice (p<0.05).
Figure 2. Resveratrol at a concentration of 10 mg/kg body weight did not increase 
survival of leukemic mice. Three groups of mice were engrafted with the t(4;11) 
ALL line SEM, and then treated intraperitoneally with either DMSO or resve-
ratrol (10 mg/kg body weight) every other day, or vincristine (0.5 mg/kg body 
weight) three times per week for 4 weeks (n=16 per treatment group). Mice were 
euthanized when they became clinically ill as described in Fig. 1. Differences 
in survival after treatment began were determined by log-rank test. The asterisk 
indicates a significant difference in survival between vincristine and DMSO or 
resveratrol treated mice (p<0.05).
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reduced by half (injection volumes between 40-60 µl) for this 
study. These smaller volumes reduced signs of discomfort and 
weakness in the mice. The mean percents of human CD19+ cells 
in the mouse PBL population at the beginning of treatment were 
not different between the groups of mice (DMSO control group 
was 3.5±3.0%; vincristine group was 1.9±1.1%; resveratrol group 
was 2.5±2.1%, p>0.05). Treatments began between 3-4 weeks 
after the injection of the leukemia cells into the mice (age 
11-12 weeks). After 4 weeks of treatment, survival curves show 
that resveratrol was similar in efficacy to the DMSO control 
(Fig. 2). Treatment with vincristine increased survival of the 
mice compared to the control mice (p<0.05, log-rank test).
Other measured parameters showed the course of disease in 
these mice. Weekly body weight measurements showed no differ-
ence between the DMSO and resveratrol treated mice and loss 
of body weight began at ~3 weeks after injection of the leukemia 
cells in both groups (age 11 weeks, Fig. 3A). Vincristine-treated 
mice weighed more than the DMSO control mice at 12 and 
13 weeks of age (20.0±1.6 vs 17.8±1.7 g, respectively at 13 weeks 
of age, p<0.05). The increasing burden of human CD19+ cells 
in peripheral blood of the mice corresponded to a reduction 
in body weight and the beginning of clinical illness (Fig. 3B). 
The percents of human CD19+ cells in the blood of DMSO and 
resveratrol treated mice were similar and were significantly 
higher than for vincristine treated mice from 12-14 weeks of 
age (p<0.05). Following euthanasia, engraftment sites of the 
SEM cells were evaluated in four mice from the DMSO control 
group. As expected for this model, substantial numbers of SEM 
cells were observed in bone marrow and spleen (>80% of total 
leukocytes), as well as the significant presence of the engrafted 
cells in the peripheral blood (Fig. 4).
Resveratrol and metabolite levels in the sera. To evaluate resve-
ratrol metabolism in the leukemic NOD/SCID mouse, surviving 
mice from the resveratrol group that were showing signs of 
clinical illness were injected i.p. with resveratrol, and euthanized 
at 1 h (n=5), 24 h (n=2), and 48 h (n=3) post injection. Results 
are summarized in Fig. 5. Assay performance was routinely 
acceptable. The 4-nitrophenyl conjugate controls indicated 
Figure 3. Loss of body weight was associated with increasing leukemia burden. 
Three groups of mice were engrafted with the t(4;11) ALL line SEM, and then 
treated intraperitoneally with either DMSO or resveratrol (10 mg/kg body 
weight) every other day, or vincristine (0.5 mg/kg body weight) three times per 
week for 4 weeks (n=16 per treatment group). (A) Body weight for each mouse 
was measured weekly beginning at age of 6 weeks. The asterisks indicate a 
difference in body weight for vincristine-treated mice compared to DMSO and 
resveratrol-treated mice (p<0.05). The arrow denotes the age of mice when the 
leukemia cells were injected. (B) PBLs were isolated from each mouse and 
stained with PE-Cy7 conjugated anti-human CD19 and APC-Cy7 conjugated 
anti-mouse CD45. The proportion of human CD19+ cells in the murine PBL 
population was monitored weekly by flow cytometry beginning 2 weeks after 
the injection of leukemia cells (age of 10 weeks) until the treatment period 
ended. The asterisks indicate a difference in the percent of CD19+ in the DMSO 
and resveratrol-treated mice compared to vincristine treated mice (p<0.05). 
Data represent means ± SD.
Figure 4. Engraftment sites for the SEM t(4;11) leukemia cells. Mice were engrafted with the t(4;11) ALL line SEM and treated with DMSO every other day 
for 4 weeks. Blood, spleens, and bone marrow were collected from 4 mice in the DMSO control group following euthanasia. Splenocytes were prepared by 
first perfusing with tissue with medium, and shredding to release the cells. The red blood cells were lysed in the blood and splenocyte preparations with 
PharmLyse. Both femurs from each mouse were removed into medium and the bone marrow was removed by perfusing the inside of the bone with medium. 
PBLs, splenocytes, and bone marrow cells were stained with PE-Cy7 conjugated anti-human CD19 and APC-Cy7 conjugated anti-mouse CD45 and analyzed 
by flow cytometry. Data are representative of four mice.
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>99% deconjugation efficiency, while d4-resveratrol recoveries 
were 68±6, 68±6 and 86±10% for the mock, β-glucuronidase and 
sulfatase digestions, respectively.
As shown in Fig. 5A, sera incubation with either β-glucu-
ronidase or sulfatase increased extractable resveratrol peak 
intensities. At 1 h post injection, serum concentrations of total 
resveratrol were ~4±2 µM, roughly distributed in a 1:3:1 ratio of 
resveratrol:resveratrol glucuronide:resveratrol sulfate (Fig. 5B). 
While traces of these metabolites were observed at 24 and 48 h, 
concentrations were <3x the instrumental detection limit of 
3.7 nM, impacting their quantitative accuracy. Additionally, the 
frequency of compound detection decreased over time (1 h = 
15/15 or 100%; 24 h = 4/6 or 67%; 48 h 3/9 or 30%). Thus, 
the leukemic NOD/SCID mouse definitively retained the ability 
to metabolize resveratrol, and at the 10 mg/kg dose, plasma 
concentrations of resveratrol were <10 nM within 24 h of i.p. 
injection.
Discussion
In a previous study, we reported that resveratrol was efficient at 
killing t(4;11) ALL cells, as well as ALL cells without the trans-
location in vitro (22). However, in the current study resveratrol 
did not reduce or delay the growth of the t(4;11) ALL cells in 
NOD/SCID mice even when it was present at a concentration 
20-fold greater than vincristine, a chemotherapeutic agent used 
in the clinical treatment of t(4;11) ALL (23). To our knowledge, 
this is the first report that i.p. administration of resveratrol does 
not kill t(4;11) ALL in vivo. The SEM cell line used for this study 
was established from a relapsed patient with ALL containing the 
translocation t(4;11) (11). We recently reported that this leukemia 
line is sensitive to vincristine in vitro, but becomes resistant to 
vincristine treatment in vivo due in part to the increased expres-
sion of the multi-drug resistant protein P-glycoprotein (25). In 
this same study, we found that vincristine was not toxic when 
administered to mice 3 times per week at a dose of 0.5 mg/kg 
body weight rather than once per week as is done for humans. 
In the present study, vincristine was able to impede the growth 
of the SEM leukemia cells for 7-14 days compared to the control 
treatment. Therefore, even though multi-drug resistant proteins 
may interfere with efficacy of therapeutic agents against this cell 
line over time, resveratrol was expected to show some ability to 
inhibit leukemia cell growth in the NOD/SCID mouse model, 
especially at a dose that was considerably higher than vincristine.
Other investigators using different cancer models have 
reported efficacy of resveratrol in inhibiting tumor cell growth. 
In a study of ovarian cancer using Balb/c nu/nu mice, resveratrol 
administered by daily i.p. injection at concentrations of 50 and 
100 mg/kg body weight for 4 weeks reduced the growth of a 
subcutaneously xenografted ovarian tumor (26). At a concen-
tration of 20 mg/kg body weight, daily i.p. administration of 
resveratrol was reported to inhibit the growth of subcutaneously 
xenografted bladder cancer (27). In the subcutaneous growth of 
tumors from Erlich's ascites, resveratrol at 20 and 40 mg/kg body 
weight was able to inhibit growth of the tumor after 20 consecu-
tive days of i.p. injections in mice (28). Neuroblastoma tumor 
growth, also subcutaneous, was similarly reported to be reduced 
when 5 mg resveratrol (per injection) was injected around the 
tumor or directly into the tumor (29).
In the present study, the dose of resveratrol in the NOD.
CB17-Prkdcscid/J mice was limited to 10 mg/kg body weight 
due to unexpected toxicity observed at 20 and 40 mg/kg body 
weight which resulted in high mortality. It is unclear why the 
leukemic mice did not tolerate the higher doses of resveratrol. 
This intolerance of leukemic NOD/SCID mice to concentra-
tions of resveratrol used in other cancer prevention studies 
may be reflective of the engraftment sites and systemic illness 
induced by this disease compared to subcutaneous xenograft 
models, and/or the intolerance may be mouse strain-dependent. 
Sites of infiltration of childhood ALL include liver, spleen, 
kidney, and central nervous system (30). Oral resveratrol has 
Figure 5. Leukemic NOD/SCID mice retain the ability to metabolize resveratrol. 
(A) Representative UPLC-MS/MS chromatograms of resveratrol isolated from 
serum collected 1 h post resveratrol i.p. injection after digestion with buffer 
(i.e., mock), sulfatase, or β-glucuronidase. Deconjugation reactions increased 
peak areas of resveratrol in serum relative to mock digestions demonstrating 
the rapid generation of glucuronide and sulfate conjugates in vivo. (B) At 1 h 
post-injection of resveratrol, mean plasma concentrations of total resveratrol 
metabolites were estimated at ~4±2 µM from 5 animals, with 17/58/25% dis-
tribution between parent, glucuronidated and sulfated metabolites. Data were 
presented as percent ± SEM. Concentrations were below the level of accurate 
quantification within 24 h, and the frequency of target analyte detection reduced 
from 67 to 30% between 24 and 48 h post-injection. LOD, limit of detection.
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shown renal toxicity in rats at a dose of 3 g/kg bodyweight (31), 
so it is possible that mice with leukemic burden in non-hemato-
logical organs, such as liver or kidney, may have an increased 
sensitivity to resveratrol toxicity after i.p. injection.
Studies have been performed in both humans and animals 
to determine the tissue distribution, excretion rates, and the 
general bioavailability of resveratrol. The majority of bioavail-
ability studies have been performed after oral administration. 
For example, 14C-labelled resveratrol at a single oral dose of 
5 mg/kg body weight was detected in the duodenum, colon, 
liver, kidney, lung, spleen, heart, brain, and testis of mice by 
3 h (32). Intraperitoneal injection of resveratrol at a dose of 
20 mg/kg body weight resulted in the predominant presence 
of both sulfate and glucuronide conjugates in mouse serum 
(33). In these experiments, 13 µM resveratrol sulfate and 5 µM 
resveratrol glucuronide were detected in the serum 15 min after 
i.p. injection, with concentrations decreasing over the next 2 h. 
In another study with gerbils, i.p. injection of resveratrol at a 
concentration of 30 mg/kg body weight resulted in approxi-
mately 20 µM resveratrol in the serum after 1 h with a decline 
to less than 1.5 µM after 24 h, with little detectable resveratrol 
present after 48 h (34). The authors reported the resveratrol was 
present mainly as the glucuronide form. Our data show a similar 
pattern of presentation of resveratrol in the serum of leukemic 
mice, in that the resveratrol was rapidly metabolized to gluc-
uronidated and sulfated conjugates within the first hour after 
i.p. injection, with a 1:3:1 distribution in the aglycone/gluronide/
sulfate forms at that time. By 24 h, serum concentrations of both 
resveratrol and its metabolites were  less than 10 nM.
The data presented in this study and the bioavailability studies 
described above show the importance of the metabolic products 
and the biological clearance of these agents when assessing the 
potential of phytochemicals as chemopreventive agents against 
leukemia. Recent reports on the biological activity of resveratrol 
metabolites showed that resveratrol sulfates can inhibit nitric 
oxide production, demonstrate radical scavenging activity, and 
inhibit cyclooxygenase-1 and -2 activities, whereas glucuronides 
had potent antioxidant potential in vitro (35-37). Resveratrol 
sulfates were also cytotoxic to breast cancer cells in vitro, but 
they were approximately 3-4-fold less toxic than resveratrol 
(38). However, the cytotoxicity observed in the latter study was 
at non-physiologic concentrations with an IC50 concentration of 
resveratrol at more than 60 µM, questioning the usefulness of 
these types of experiments. Parenterally administered resveratrol 
is metabolized to conjugated chemical forms that are either not 
cytotoxic or not at sufficient concentrations to induce apoptotic 
cell death in t(4;11) ALL cells in vivo. Caution should be exercised 
in future in vitro and in vivo research with phytochemicals for 
the potential prevention of t(4;11) or other ALLs, and researchers 
will need to consider the effects of metabolic alterations that 
occur in vivo. Finally, we note that while resveratrol by itself was 
not efficacious in the current study, it has been argued that resve-
ratrol may be of value as a complementary agent in the treatment 
of select cancers (39). This is a possibility that clearly merits 
additional study with respect to the potential value of resvera-
trol in treating ALL. However, it is equally important to note 
that resveratrol has been reported to blunt the actions of select 
chemotherapeutic agents, such as proteasome inhibitors and 
paclitaxel (40,41). The above underscores the need to not only 
consider the impact of absorption, distribution, metabolism, and 
excretion of resveratrol and its subsequent biological actions, but 
also the possibility of resveratrol having deleterious side effects.
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